AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25131839
Drug: Curcumin extract
RxNorm normalized name: Curcumin Extract 300 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin extract (630mg thrice daily)
Trial: 25131839
Drug: Placebo (thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (thrice daily)
Trial: 23303874
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg daily)
Trial: 15678413
Drug: Ordered categorical
RxNorm normalized name: Orderable Drug Form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordered categorical doses of antidepressants
Trial: 12670818
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg.kg(‐1) iv (maximum dose 8 mg)
Trial: 27435791
Drug: nifuratel-500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifuratel-500 (500 mg nifuratel, intravaginal, 10 days)
Trial: 27435791
Drug: nifuratel-250 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifuratel-250 (250 mg nifuratel, intravaginal, 10 days)
Trial: 16095462
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 10 mg/h + morphine 0.16 mg/h (Group L)
Trial: 16095462
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 16 mg/h + morphine 0.16 mg/h (Group H)
Trial: 16095462
Drug: Placebo PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PCA morphine (Group PL)
Trial: 7791061
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% apraclonidine, one drop before and after surgery
Trial: 7791061
Drug: Sustained-release acetazolamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release acetazolamide, 500 mg
Trial: 2152944
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro best regimen (IVBR), a three-drug combination of proved efficacy in SCLC, administered as secondary therapy to patients with partial or no responses after primary therapy.
Trial: 2152944
Drug: Empiric combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric combination of vincristine-doxorubicin-cyclophosphamide, administered as secondary therapy when DST data were unavailable.
Trial: 2152944
Drug: Primary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary therapy with etoposide and cisplatin, followed by restaging after 12 weeks.
Trial: 2152944
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro drug sensitivity testing (DST) data used to select chemotherapy.
Trial: 2152944
Drug: IVBR as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVBR as secondary therapy.
Trial: 359121
Drug: 5FU infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5FU infusion with Mitomycin-C
Trial: 359121
Drug: 5FU infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5FU infusion with Methyl-CCNU
Trial: 29408760
Drug: Zataria multiflora
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zataria multiflora 5 mg/kg/day
Trial: 29408760
Drug: Zataria multiflora
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zataria multiflora 10 mg/kg/day
Trial: 22354664
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO2) at 3 ATA for 10 consecutive days
Trial: 19818077
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg once daily (od) alone
Trial: 19818077
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg od combined with simplified bladder training
Trial: 19818077
Drug: Solifenacin 10
RxNorm normalized name: solifenacin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 10 mg od (after dose increase)
Trial: 17605004
Drug: Tramadol 200
RxNorm normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 200 mg
Trial: 17605004
Drug: Tramadol 400
RxNorm normalized name: tramadol hydrochloride 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 400 mg
Trial: 17605004
Drug: Naloxone 0.1
RxNorm normalized name: naloxone 0.18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.1 mg IM
Trial: 17605004
Drug: Naloxone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.2 mg IM
Trial: 17605004
Drug: Morphine 15
RxNorm normalized name: morphine 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 15 mg IM
Trial: 17605004
Drug: Morphine 30
RxNorm normalized name: ethylmorphine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 30 mg IM
Trial: 10359389
Drug: Metformin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (in obese patients)
Trial: 8530606
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR 20 mg
Trial: 8530606
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR 30 mg
Trial: 8530606
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR (3, 6, 9, or 12 mg)
Trial: 1779103
Drug: Gel‐Larmes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel‐Larmes
Trial: 6123069
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Dihydergot (0.25 mg i.v.) and etilefrine (15 mg p.o.)
Trial: 6123069
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Dihydergot (2 mg) and etilefrine (20 mg)
Trial: 6114845
Drug: Etilefrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etilefrine (20 mg)
Trial: 6123069
Drug: Dihydergot (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydergot (2 mg)
Trial: 28826740
Drug: Parnaparin sodium
RxNorm normalized name: parnaparin sodium
DrugBank: Parnaparin (DB09260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin sodium (low-molecular weight heparin) for the whole cycle
Trial: 28826740
Drug: Routine hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine hormonal therapy only
Trial: 21419287
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of 4% articaine with 1:100,000 epinephrine
Trial: 21419287
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of 1 mL/30 mg of ketorolac tromethamine (after 0.9 mL of 4% articaine)
Trial: 21419287
Drug: Supplemental buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental buccal infiltration of 1 mL/4 mg of dexamethasone
Trial: 19548436
Drug: Qihong Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qihong Decoction (QHD) combined with routine treatment
Trial: 16787719
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/day) for 6 months
Trial: 14747233
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg b.i.d. for 12 weeks
Trial: 14747233
Drug: rosiglitazone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone with co-infusion of exogenous insulin
Trial: 14747233
Drug: nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide 60 mg b.i.d. for 12 weeks
Trial: 1908192
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of epidural diamorphine at a rate of 1 mg/hour (group 1)
Trial: 1908192
Drug: Bolus doses
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus doses of epidural diamorphine 5 mg on demand (group 2)
Trial: 20046181
Drug: Immunochromatographic test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochromatographic test (ICT) for antibody
Trial: 19040391
Drug: Ayurvedic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic formulation 'varuna and banana stem' (active treatment)
Trial: 30043092
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 70 micro g/day (2800 IU/day)
Trial: 22215183
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU vitamin D3 monthly
Trial: 22215183
Drug: Single 50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 50,000 IU dose pre-departure
Trial: 17394627
Drug: Biatain-Ibu non
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biatain-Ibu non adhesive foam dressing with ibuprofen
Trial: 17394627
Drug: Biatain non
RxNorm normalized name: DRESSING,BIATAIN NON-ADHES FOAM 2X2.75IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biatain non adhesive foam without ibuprofen
Trial: 10671963
Drug: Nels cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nels cream (containing chloroxylenol and zinc oxide)
Trial: 10671963
Drug: Vehicle of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of the Nels cream
Trial: 1552408
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of nebulized cromolyn sodium
Trial: 4053214
Drug: Lenampicillin (LAPC)
RxNorm normalized name: methampicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenampicillin (LAPC) - single dose (250 mg)
Trial: 4053214
Drug: Amoxicillin (AMPC)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMPC) - single dose (500 mg)
Trial: 4053214
Drug: Lenampicillin (LAPC)
RxNorm normalized name: methampicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenampicillin (LAPC) - multiple dose (250 mg twice a day for 8 days)
Trial: 4053214
Drug: Amoxicillin (AMPC)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMPC) - multiple dose (500 mg twice a day for 8 days)
Trial: 4053214
Drug: Amoxicillin (AMPC)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AMPC)
Trial: 29466159
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg daily for 5 days, then continued or switched to aspirin)
Trial: 25524327
Drug: 60 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg/day selenium
Trial: 20068435
Drug: Sonography-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonography-guided injection of botulinum toxin A into calf muscles
Trial: 20068435
Drug: Electric stimulation-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electric stimulation-guided injection of botulinum toxin A into calf muscles
Trial: 16232016
Drug: Fat emulsion
RxNorm normalized name: FAT EMULSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat emulsion administered through the ECMO circuit (1-3 g/kg/day)
Trial: 16232016
Drug: Fat emulsion
RxNorm normalized name: FAT EMULSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat emulsion administered through separate intravenous access (1-3 g/kg/day)
Trial: 9810316
Drug: Short-course preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course preoperative radiation therapy
Trial: 9810316
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy with conventional doses and concurrent fluorouracil-based chemotherapy
Trial: 9810316
Drug: Postoperative combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative combination therapy
Trial: 11362207
Drug: ABT-538 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-538 (300 mg, 400 mg, 500 mg, or 600 mg, administered twice daily)
Trial: 979871
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (bicycle ergometer training for 15 minutes, 3 times weekly at 140 bpm)
Trial: 30986535
Drug: Oral naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone (O-NTX)
Trial: 26940112
Drug: Recovery-focused Cognitive
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery-focused Cognitive Behavioural Therapy for Older Adults (RfCBT-OA) plus treatment as usual (TAU)
Trial: 24698798
Drug: Withholding dopaminergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding dopaminergic medication (OFF meds) during split-belt treadmill (SBT) walking
Trial: 22369555
Drug: Full-mouth scaling
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth scaling and root planing (treatment group, n = 22)
Trial: 22369555
Drug: No periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No periodontal treatment (control group, n = 18)
Trial: 15827447
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg or 10 mg) once daily for up to 5 years
Trial: 15827447
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg) once daily for up to 5 years
Trial: 8913472
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% erythromycin
Trial: 30900426
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with Fagales pollen extracts
Trial: 23173418
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment at 3.5 W in group A
Trial: 23173418
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment at 4.0 W in group B
Trial: 23173418
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment at 4.5 W in group C
Trial: 23173418
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group D (no treatment)
Trial: 15786480
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) combined with photodynamic therapy (PDT) using systemic 5-aminolaevulinic acid (5-ALA) as the photosensitiser
Trial: 30721231
Drug: EuroFIT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EuroFIT intervention (12-week, group-based programme delivered in 12 weekly 90-minute sessions)
Trial: 27751217
Drug: High-dose gamma
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gamma globulin pulse therapy
Trial: 19404806
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine (total volume 106 mL) infiltrated intraoperatively
Trial: 19404806
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine injected intraarticularly via a catheter 21 hours postoperatively
Trial: 17984806
Drug: 30 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mug Vi polysaccharide vaccine (revaccination)
Trial: 17984806
Drug: Vi polysaccharide
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide vaccine (primary vaccination)
Trial: 9884851
Drug: Morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.2 mg mL‐1 plus lignocaine 3.2 mg mL‐1 (group ML)
Trial: 9884851
Drug: Morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.2 mg mL‐1 (group M)
Trial: 25828348
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg losartan daily
Trial: 25828348
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg losartan daily
Trial: 25828348
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose losartan
Trial: 23955995
Drug: Metformin (lean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (lean subgroup, BMI < 25 kg/m(2))
Trial: 19410976
Drug: (1,3)(1,6)-beta-D-glycan (BDG)
RxNorm normalized name: beta-D-ribose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1,3)(1,6)-beta-D-glycan (BDG) 3 x 0.5 g daily for 4 weeks
Trial: 19410976
Drug: Placebo (waxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (waxy maize starch) 3 x 0.5 g daily for 4 weeks
Trial: 8197931
Drug: Radical prostatectomy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical prostatectomy after hormonal treatment (560 mg of estramustine phosphate daily for 6 weeks)
Trial: 29093779
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HA and DBM
Trial: 23784924
Drug: Methylprednisolone 16
RxNorm normalized name: methylprednisolone 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 16 mg/kg/day (≤1000 mg) for 3 days
Trial: 12953307
Drug: CDDP/epi gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP/epi gel
Trial: 10081698
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal treatment (NHT) for three months
Trial: 1838772
Drug: Couple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple therapy (n = 33), consisting of five monthly sessions attended by two family therapists.
Trial: 1838772
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without couple therapy (n = 30).
Trial: 24622016
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 0.5 mg/1 ml
Trial: 24622016
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 2 mg/1 ml
Trial: 24622016
Drug: Sodium Chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride (NS) 0.9% solution (1 ml)
Trial: 20528293
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure (VRE) therapy
Trial: 20528293
Drug: Present‐centered therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present‐centered therapy (PCT)
Trial: 18808630
Drug: Music group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music group (listened to selected sedative music using headphones)
Trial: 10230185
Drug: Antipsychotic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic agents
Trial: 1646182
Drug: Fluoxetine (FXT)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FXT) 60 mg daily (n = 11)
Trial: 8555377
Drug: Fluoxetine (FXT)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FXT)
Trial: 6941408
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg domperidone i.v.
Trial: 28249030
Drug: Fixed low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed low dose ESA (4000 IU epoetin alfa equivalent weekly)
Trial: 28249030
Drug: Fixed high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed high dose ESA (18,000 IU epoetin alfa equivalent weekly)
Trial: 25161160
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus voglibose